# US 2024/0189447 A1 · Rational polyploid aav virions that cross the blood brain barrier and elicit reduced humoral response

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189447 A1
- Document ID: US20240189447A1
- Status: Published application
- Kind: A1
- Application number: 18/286,709
- Filed: 2022-04-14
- Published: 2024-06-13
- Earliest claimed: 2021-04-16
- Assignees: Asklepios Biopharmaceutical, Inc.
- Applicants: Asklepios Biopharmaceutical, Inc.
- Inventors: Lester Suarez; Amaury Pupo Merino; Audry Fernandez
- Web page: https://patentgrep.com/patent/US20240189447A1

## CPC

- A61K 48/0041: {the non-active part being polymeric}
- A61P 25/00: Drugs for disorders of the nervous system
- A61K 35/76: Viruses; Subviral particles; Bacteriophages
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 15/86: Viral vectors
- A61K 2039/577: {tolerising response}
- C12N 2750/14122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2750/14145: Special targeting system for viral vectors
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to a substantially homogenous population of a rational polyploid adeno-associated virus (AAV) virons that cross the blood brain barrier (BBB), where the rational polyploid comprises a VP3 viral structural protein from any AAV serotype that cross the BBB. In some embodiments, the rational polyploid crosses the BBB upon systemic or intrathecal administration to a subject. In some embodiments, a rational polyploid AAV virion comprises at least one VP1 and/or VP2 viral structural protein in addition to the VP3 protein. In some embodiments, the VP3 capsid protein is from a non-human primate, and in some embodiments the VP3 capsid protein is a AAV rhesus monkey serotype. In specific embodiments, rational polyploid AAV virion comprises a VP1 capsid protein from AAV8, and at least a VP3 capsid protein from any AAV serotype that cross the BBB.

## Claims

### Claim 1

A population of rational polyploid AAV virions suitable for use in crossing the blood brain barrier, the rational polyploid AAV virions comprising at least one of AAV VP1 or VP2 viral structural proteins and an AAV VP3 viral structural protein;
wherein the at least one of VP1 or VP2 viral structural proteins are each from any AAV serotype, and the VP3 viral structural protein is from an AAV serotype that efficiently crosses the blood brain barrier and is different from the serotype of at least one of VP1 or VP2, and
wherein the population of rational polyploid AAV virions is capable of crossing the blood brain barrier (BBB) and/or transducing an endothelial cell of the BBB and/or a blood component that crosses the BBB upon systemic or intrathecal administration.

### Claim 2 (depends on 1)

The population of claim 1, wherein the population exhibits enhanced transduction activity across the blood brain barrier (BBB) relative to a non-rational polyploid AAV particle that lacks ability to cross the blood brain barrier.

### Claim 3 (depends on 1, 2)

The population of any of claims 1-2, wherein the VP3 viral structural protein is an AAV rhesus monkey serotype.

### Claim 4 (depends on 1, 2, 3)

The population of any of claims 1-3, wherein the VP3 viral structural protein is from a serotype that efficiently crosses the blood brain barrier selected from the group consisting of AAV1, AAV6, AAV6.2, AAV7, AAV9, AAVrh10, AAVrh74, AAVrh39, and AAVrh43.

### Claim 5 (depends on 1, 2, 3, 4)

The population of any of claims 1-4, wherein the population has enhanced transduction to one or more of cortex, striatum, thalamus, medulla, hippocampus, cerebellum and spinal cord of a subject relative to a non-rational polyploid AAV particle that lacks ability to efficiently cross the blood brain barrier.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The population of any of claims 1-5, wherein, the population has enhanced transduction relative to AAV2 in one or more of CNS regions selected from the group consisting of medulla, cervical, thoracic, lumbar, and choroid plexus.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The population of any of claims 1-6, wherein the population has enhanced binding to brain microvascular endothelial cell (BMVEC) relative to AAV8.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The population of any of claims 1-7, wherein the population has biodistribution in the CNS.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The population of any of claims 1-8, wherein the population has CNS biodistribution of at least 0.05 vg/cell, 0.1 vg/cell, at least 0.2 vg/cell, at least 0.4 vg/cell, at least 0.6 vg/cell, at least 0.8 vg/cell, at least 1 vg/cell, at least 5 vg/cell, at least 10 vg/cell, at least 20 vg/cell, at least 25 vg/cell, or preferably more.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The population of any of claims 1-9, wherein the at least one of VP1 or VP2 is selected from an AAV serotype that crosses blood brain barrier.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The population of any of claims 1-9, wherein the at least one of VP1 or VP2 is selected from an AAV serotype that do not cross blood brain barrier.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The population of any of claims 1-11, wherein that least one of VP1 or VP2 is not selected from AAV rhesus monkey serotype.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The population of any of claims 1-11, wherein the at least one of VP1 or VP2 is selected from an AAV rhesus monkey serotype.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The population of any of claims 1-13, wherein the population elicits a lower humoral immune response when administered to a subject as compared to a humoral response as elicited by a parental AAV vector of the subtype of the VP1 or VP2 structural protein.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The population of any of claims 1-14, wherein the population evades neutralizing antibodies against the parental serotypes of AAV VP1, VP2, or VP3 viral structural proteins.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

A method for delivering a transgene across the blood brain barrier of a subject, the method comprising administering to the subject a population of rational polyploid AAV virions of any of claims 1-15.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

A method for repeat dosing of AAV to a subject, the method comprising a first administration performed by administering to the subject the population of rational polyploid AAV virions from any of claims 1-16, and a second administration performed by administering to the subject parental AAV serotypes of the at least one of VP1 or VP2 viral structural protein,
wherein the population of rational polyploid AAV virions elicits a reduced humoral response in the subject as compared to a humoral response as elicited by the parental AAV serotypes of the VP1 or VP2 viral structural protein, and
wherein the at least one of the VP1 or VP2 is not from a Rhesus AAV serotype.

### Claim 18

A population of rational polyploid AAV virions that allows repeat dosing, the population comprising:
a rational polyploid AAV virion comprising at least one of AAV VP1 or VP2 viral structural proteins and a AAV VP3 viral structural protein;
wherein the at least one of VP1 or VP2 viral structural proteins are each from any AAV viral serotype, and the VP3 viral structural protein is selected from a rhesus monkey AAV serotype;
wherein the population of rational polyploid AAV virions elicits a reduced humoral response as compared to a humoral response elicited by the parental AAV serotype of the VP1 or VP2 viral structural proteins;
wherein the at least one of VP1 or VP2 are not from a Rhesus AAV serotype, and
wherein the repeat dosing comprises a first administration of the population of rational polyploid AAV virions and a second administration of a parental AAV serotype of the VP1 structural viral protein or VP2 structural viral protein.

### Claim 19

A population of rational polyploid AAV virions, the population comprising:
a. VP1 and VP2 AAV viral structural proteins selected from an AAV8 viral serotype, and
b. VP3 selected from an AAV rhesus monkey serotype AAV rh10 or AAVrh74,
wherein the population of rational polyploid AAV virions elicits a reduced humoral response when administered to a subject relative to a corresponding humoral response elicited by a parental AAV8 serotype.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 18, 19)

A method for repeat dosing comprising first and second AAV administrations to a subject, the method comprising:
the first administration performed by administering to the subject a population of rational polyploid AAV virions from any of claims 1-16 or 18-19, and
the second administration performed by administering the parental AAV serotype of VP1 or VP2 viral structural proteins,
wherein the first administration elicits a reduced humoral response in the subject as compared to a corresponding humoral response as elicited by the parental AAV serotypes of VP1 or VP2 viral structural protein, and
wherein VP1 or VP2 are not from a Rhesus AAV serotype.

### Claim 21 (depends on 18, 19, 20)

The population of any of claims 18-20, wherein the population evades neutralizing antibodies against the parental serotypes of AAV VP1, VP2, or VP3 viral structural proteins.

### Claim 22 (depends on 18, 19, 20, 21)

A method for delivering a transgene across the blood brain barrier of a subject, the method comprising administering to the subject the population of rational polyploid AAV virions of any of claims 18-21.

### Claim 23

The population of any of the preceding claims, wherein the VP3 protein is a mutated VP3 protein from AAVrh10 or AAVrh74 serotype.

### Claim 24 (depends on 23)

The population of claim 23, wherein the mutated AAVrh74 VP3 protein has the amino acid sequence of SEQ ID NO: 2 or a protein having at least 85% sequence identity to SEQ ID NO: 2, or wherein the mutated AAVrh74 VP3 comprises at least one of the following modifications of SEQ ID NO: 2: N263S, G264A, T265S, S266T, G268A, T270del, T274H, E533K, R726H, N736P.

### Claim 25 (depends on 24)

The population of claim 24, wherein the mutated AAVrh10 VP3 protein is encoded by a nucleic acid of SEQ ID NO: 5 that comprises at least one or more of: Q214N, S462N and D517E mutations as compared to AAVrh10_VP3 nucleic acid of SEQ ID NO: 5, or comprises a nucleic acid sequence having at least 85% sequence identity to SEQ ID NO: 5 comprising at least one mutation selected from Q214N, S462N and D517E.

### Claim 26 (depends on 25)

The population of claim 25, wherein the VP3 protein is a AAVrh74 VP3 protein comprising the amino acid sequence of SEQ ID NO: 2 or 3 or a protein having at least 85% sequence identity to SEQ ID NO: 2 or SEQ ID NO: 3, or comprises at least one of the following amino acid modifications of N263S, G264A, T265S, S266T, G268A, T270del, T274H, E533K, R726H, N736P of SEQ ID NO: 2.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

A substantially homogenous population of virions of any of claims 1-26, wherein the population is at least 101 virions.

### Claim 28

A nucleic acid comprising, in a 5′ to 3′ direction:
a. a first nucleic acid encoding an AAVrh10 VP3 capsid protein operatively linked to a first promoter;
b. a first poly A sequence;
c. a second nucleic acid encoding a rep protein;
d. a third nucleic acid encoding AAV8 VP1 and VP2 viral structural proteins, the third nucleic acid sequence not being capable of expressing an AAV8 VP3 viral structural protein; and
e. a second poly A sequence.

### Claim 29

A nucleic acid comprising, in a 5′ to 3′ direction:
a. a first nucleic acid encoding a AAVrh74 VP3 capsid protein operatively linked to a first promoter;
b. a first poly A sequence;
c. a second nucleic acid encoding a rep protein;
d. a third nucleic acid encoding AAV8 VP1 and VP2 viral structural proteins, the third nucleic acid sequence not being capable of expressing a AAV8 VP3 viral structural protein; and
e. a second poly A sequence.

### Claim 30

A viral vector comprising:
a. an AAV virion from the population of any of the proceeding claims; and
b. a nucleic acid comprising at least one terminal repeat sequence and a heterologous gene, wherein the nucleic acid is encapsulated by the AAV virion.

### Claim 31

The population of any of the preceding claims comprising a chimeric or modified viral structural protein, wherein the modified viral structural protein comprises insertion, deletion or, substitution of one or more amino acids.

### Claim 32 (depends on 27)

The substantially homogenous population of claim 27, wherein the substantially homogenous population elicits significantly fewer anti-AAV IgG antibodies against parental AAV serotypes of VP1 or VP2 structural proteins in serum in vivo as compared to a substantially homogenous population of virions comprising parental AAV serotype.

### Claim 33 (depends on 32)

The substantially homogeneous population of claim 32, wherein the parental AAV serotype is AAV8.

### Claim 34

A population of rational polyploid AAV virions that allow repeat dosing, the population comprising:
at least one of AAV VP1 or VP2 viral structural proteins and a AAV VP3 viral structural protein;
wherein the VP1 and VP2 viral structural proteins are each from any AAV viral serotype except for a Rhesus AAV serotype, and the VP3 viral structural protein is selected from a rhesus monkey AAV serotype;
wherein the population of rational polyploid AAV virions evade neutralizing antibodies against a parental AAV rhesus monkey serotype of the VP3 viral structural protein,
wherein the repeat dosing comprises a first administration of the parental AAV rhesus monkey serotype of the VP3 structural protein and a second administration of the population of rational polyploid AAV virions, and
wherein the VP3 structural protein of the rational polyploid virions is a AAV rhesus monkey mutated viral structural protein VP3.

### Claim 35 (depends on 34)

The population of rational polyploid AAV virions of claim 34, wherein the AAV rhesus monkey mutated viral structural protein VP3 is from a mutated AAV rh10 VP3 viral structural protein or from a mutated AAV rh74 VP3 viral structural protein.

### Claim 36 (depends on 34, 35)

The population of rational polyploid AAV virions of any of claims 34-35, wherein the mutated viral structural protein VP3 comprises a mutation at an amino acid that corresponds to an amino acid selected from the group consisting of N263, G264, T265, S266T, G268, T270, T274, and E533, wherein all the amino acid positions correspond to a native VP1 sequence numbering of AAV rh10 or AAVrh74.

### Claim 37 (depends on 36)

The population of claim 36, wherein the mutation is selected from the group consisting of N263S, G264A, T265S, S266T, G268A, T270del, T274H, and E533K.

### Claim 38 (depends on 34, 35, 36, 37)

The population of rational polyploid AAV virions of any of claims 34-37, wherein the mutated viral structural protein VP3 further comprises a mutation at an amino acid that corresponds to an amino acid selected from the group consisting of R727 and N737, wherein all the amino acid positions correspond to a native VP1 sequence numbering of AAVrh10.

### Claim 39 (depends on 38)

The population of rational polyploid AAV virions of claim 38, wherein the mutation is selected from the group consisting of R727H and N737P.

### Claim 40 (depends on 34, 35, 36, 37)

The population of rational polyploid AAV virions of any of claims 34-37, wherein the mutated viral structural protein VP3 further comprises a mutation at an amino acid that corresponds to an amino acid selected from the group consisting of R726 and N736, wherein all the amino acid positions correspond to a native VP1 sequence numbering of AAV rh74.

### Claim 41 (depends on 40)

The population of rational polyploid AAV virions of claim 40, wherein the mutation is selected from the group consisting of R726H and N736P.

### Claim 42 (depends on 41)

The population of rational polyploid AAV virions of claim 41, wherein the mutated viral structural protein VP3 further comprises a mutation at an amino acid that corresponds to W at 581, wherein the W is replaced by two subsequent V residues (VV) and wherein all amino acid positions correspond to a native VP1 sequence numbering of AAV rh74.

### Claim 43 (depends on 34, 35, 36, 37, 38, 39, 40, 41, 42)

The population of rational polyploid AAV virions of any of claims 34-42, wherein the AAV VP1 or VP2 viral structural protein is any AAV serotype selected from Table 1.

### Claim 44 (depends on 34, 35, 36, 37, 38, 39, 40, 41, 42, 43)

The population of rational polyploid AAV virions of any of claims 34-43, wherein the AAV VP1 or VP2 structural protein is AAV8.

### Claim 45 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 18, 19, 21, 23, 24, 25, 26, 27, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

Use of a population of rational polyploid AAV virions in the manufacturer of a medicament for use for delivering a transgene across a blood brain barrier, the medicament comprising a population of rational polyploid AAV virions of any of claims 1-15 or 18-19, 21, 23-27, 31-44.

### Claim 46 (depends on 45)

The use of claim 45, wherein the population of rational polyploid AAV virions comprises VP1 and VP2 AAV viral structural proteins selected from an AAV8 viral serotype, and VP3 viral structural protein selected from an AAV rhesus monkey serotype AAV rh10 or AAVrh74.

### Claim 47 (depends on 45)

The use of claim 45, wherein the population of rational polyploid AAV virions comprises VP1 and VP2 AAV viral structural proteins from an AAV8 viral serotype, and a VP3 structural protein from an AAV rhesus monkey serotype AAVrh74.

### Claim 48 (depends on 45)

The use of claim 45, wherein the medicament is useful to treat a brain disease or brain disorder or a neurodegenerative disease, or a neurological disease.

### Claim 49 (depends on 45)

The use of claim 45, wherein the medicament is useful to treat diseases of the central nervous system (CNS) or peripheral nervous system (PNS).

### Claim 50 (depends on 45)

The use of claim 45, wherein the medicament is useful to treat a subject with a brain cancer or cancer in the brain.

### Claim 51 (depends on 45)

The use of claim 45, wherein the medicament is useful to treat a subject with a disease or disorder selected from: Alzheimer's disease, Huntington's disease, Parkinson's disease, Amyotrophic Lateral sclerosis (ALS), and Dopamine transporter deficiency syndrome.

### Claim 52 (depends on 28, 29)

Use of a nucleic acid in the manufacturer of a medicament comprising a population of rational polyploid AAV virions for use for delivering a transgene across a blood brain barrier, the nucleic acid comprising any of claims 28 or 29.

### Claim 53 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 18, 19)

Use of a population of rational polyploid AAV virions in the preparation of a first medicament and a second medicament for use in a method for repeat dosing of a first administration of the first medicament and second administration of the second medicament, wherein the repeat dosing comprises the first administration of the first medicament comprising a rational polyploid AAV virion from any of claims 1-15 or 18-19, and the second administration of the second medicament comprising a parental AAV serotypes of the at least one of VP1 or VP2 viral structural protein,
wherein the population of rational polyploid AAV virion elicits a reduced humoral response as compared to a humoral response as elicited by the parental AAV serotypes of the at least one of the VP1 or VP2 viral structural protein, and wherein the VP1 or VP2 is not from a Rhesus AAV serotype.

### Claim 54 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 18, 19, 21, 23, 24, 25, 26, 27, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

Use of a population of rational polyploid AAV virions in the preparation of a medicament for evading neutralizing antibodies against parental serotypes of AAV VP1, VP2, or VP3 the medicament comprising a population of rational polyploid AAV virions of any of claims 1-15 or 18-19, 21, 23-27 and 31-44.

### Claim 55 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 18, 19, 21, 23, 24, 25, 26, 27, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

Use of a population of rational polyploid AAV virions in the preparation of a medicament for delivering a transgene to the small intestine, the medicament comprising the population of rational polyploid AAV virions of any of claims 1-15 or 18-19, 21, 23-27 and 31-44.

### Claim 56 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 18, 19, 21, 23, 24, 25, 26, 27, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

Use of a population of rational polyploid AAV virions in the preparation of a medicament for the treatment of a gastrointestinal disease or disorder, the medicament comprising the population of rational polyploid AAV virions of any of claims 1-15 or 18-19, 21, 23-27 and 31-44.
